Savara (NASDAQ:SVRA) Rating Reiterated by JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Savara (NASDAQ:SVRA) in a research report released on Thursday, Benzinga reports. JMP Securities currently has a $8.00 price target on the stock.

Separately, Piper Sandler lifted their price target on shares of Savara from $7.00 to $16.00 and gave the company an overweight rating in a report on Monday, March 4th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus price target of $8.20.

Savara Price Performance

NASDAQ:SVRA opened at $4.79 on Thursday. The company has a 50-day moving average of $4.97 and a 200-day moving average of $4.39. The company has a market capitalization of $661.74 million, a price-to-earnings ratio of -14.52 and a beta of 0.77. Savara has a 52 week low of $1.76 and a 52 week high of $5.70. The company has a debt-to-equity ratio of 0.19, a quick ratio of 15.66 and a current ratio of 15.66.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. As a group, equities research analysts anticipate that Savara will post -0.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sivia Capital Partners LLC acquired a new stake in Savara in the 4th quarter valued at about $169,000. Vanguard Group Inc. increased its position in Savara by 2.6% in the 4th quarter. Vanguard Group Inc. now owns 5,914,947 shares of the company’s stock valued at $27,800,000 after acquiring an additional 150,346 shares in the last quarter. Wellington Management Group LLP acquired a new stake in Savara in the 4th quarter valued at about $9,683,000. Goldman Sachs Group Inc. increased its position in Savara by 44.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 127,200 shares of the company’s stock valued at $598,000 after acquiring an additional 38,895 shares in the last quarter. Finally, Barclays PLC increased its position in Savara by 673.4% in the 4th quarter. Barclays PLC now owns 123,956 shares of the company’s stock valued at $582,000 after acquiring an additional 107,928 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.